Exclusion of Abortion and Abortion Counseling from the VA Medical Benefits Package
Comment: Submitted to the U.S. Department of Veterans Affairs
Population Health
Policy
Patient Focused Drug Development: Methodologic and Other Challenges Related to Patient Experience Data
Comment: Submitted to the Food and Drug Administration and Department of Health and Human Services
Print:
On December 18, 2024, LDI Senior Fellow Sean Hennessy, PharmD, PhD submitted a comment in response to a Request for Comments from the U.S Food and Drug Administration and U.S. Department of Health and Human Services. The request sought input regarding methodological challenges related to data on patient experience.
As an expert in pharmacoepidemiology, the study of the health effects of drugs and other medical products in populations, Dr. Hennessy provides 10 suggestions for improving the use of patient experience data in patient focused drug development.
Views expressed by the researchers are their own and do not necessarily represent those of the University of Pennsylvania Health System (Penn Medicine) or the University of Pennsylvania.
More on Policy at LDI
Impact of Proposed Changes to the Application of the Fair Labor Standards Act to Domestic Service on the Home Care Workforce
Comment: Delivered to the U.S. Department of Labor
Policy Recommendations for Strengthening the Accelerated Approval Program for Oncology Drugs
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Estimated Overdose Deaths Due to the One Big Beautiful Bill Act
Letter: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Health Impacts of SNAP Provisions in the One Big Beautiful Bill Act
Letter: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Impact of House Budget Reconciliation Bill on Insurance Coverage
Comment: Delivered to the Senate Committee on Health, Education, Labor, and Pensions